Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
86.04
+0.57 (0.67%)
Apr 14, 2026, 3:00 PM CST
Market Cap53.18B +215.1%
Revenue (ttm)4.20B +251.8%
Net Income2.94B +317.1%
EPS4.76 +317.5%
Shares Out618.09M
PE Ratio18.08
Forward PE82.73
Dividend0.12 (0.14%)
Ex-Dividend DateNov 7, 2025
Volume10,640,814
Average Volume12,190,881
Open85.18
Previous Close85.47
Day's Range82.41 - 86.75
52-Week Range26.80 - 96.60
Beta0.55
RSI64.31
Earnings DateMar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,023
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.94 billion, an increase of 317.09%.

Financial Statements